THERAPIX BIOSCI/S ADR TRPX said Tuesday that it has signed a letter of intent for a merger with the Canadian cannabis company Destiny Biosciences.
The deal is a stock-for-stock transaction valuing Therapix at about $48 million plus cash on hand at closing. The deal values the combined company at about $151 million, Therapix said.
The Israeli cannabinoid pharmaceutical company said it expects a definitive agreement to be struck in the third quarter of this year; upon closing, Therapix equity holders are anticipated to hold about 32% of the combined company.
Benzinga's Cannabis Capital Conference heads to Detroit on Aug. 15 — click here to learn more!
"Combining the two companies creates a unique patented and valuable opportunity to create unique and very specific cannabis-based medicinal formulations literally from seed to sale, and the companies have already identified and commenced work in immediate areas of interest," according to Therapix.
The stock was trading higher by 71.3% at $3.94 at the time of publication Tuesday. The stock has a 52-week high of $9.30 and a 52-week low of $2.22.
Never miss a news story in the cannabis world. Click here to check out Benzinga Cannabis for more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!